In May 2019, ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, became the first US Food and Drug Administration–approved treatment for steroid-refractory acute GVHD in patients ≥12 years old [23]. The gene discussed is JAK2; the disease is acute graft versus host disease.